Business Context and Reporting Period
This Form 8-K Current Report was filed by Renovaro Biosciences Inc. (not Lunai Bioworks Inc.) on October 10, 2023, with the earliest event reported on that same date. The filing discloses corporate governance changes and a new material agreement.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed relates to equity compensation:
- Equity Grant: 1,000,000 shares of restricted stock issued to a new director.
Material Changes
The primary material change reported is the appointment of Avram Miller to the Board of Directors, effective October 11, 2023, to fill a vacancy. Mr. Miller, a co-founder of Intel Capital, will serve until the 2024 Annual Meeting of Stockholders or until a successor is elected.
Guidance, Outlook, and Management Commentary
Advisory Agreement: Concurrent with his board appointment, Mr. Miller entered into an advisory agreement to provide counsel on strategic opportunities, capital allocation, business development, minority investments, and licensing arrangements.
Compensation Structure: The 1,000,000 shares of restricted stock vest as follows:
- 166,667 shares in 2024
- 444,444 shares in 2025
- 388,889 shares in 2026
Regulatory Disclosure: The company issued a press release on October 11, 2023, regarding these events (Exhibit 99.1). The filing explicitly states that the press release information is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the Advisory Agreement, which is scheduled to be filed as an exhibit to the next Form 10-Q.
- Confirm the impact of the 1,000,000 share grant on total outstanding shares and potential dilution.
- Review the October 11, 2023 press release (Exhibit 99.1) for additional strategic context not detailed in the 8-K.
- Note that the filing contains no financial results; refer to the most recent 10-Q or 10-K for financial health metrics.